These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

346 related articles for article (PubMed ID: 11705350)

  • 1. Targeting tumor necrosis factor alpha. New drugs used to modulate inflammatory diseases.
    LaDuca JR; Gaspari AA
    Dermatol Clin; 2001 Oct; 19(4):617-35. PubMed ID: 11705350
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TNF-α antagonists beyond approved indications: stories of success and prospects for the future.
    Karampetsou MP; Liossis SN; Sfikakis PP
    QJM; 2010 Dec; 103(12):917-28. PubMed ID: 20802008
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Management of severe psoriasis with TNF antagonists. Adalimumab, etanercept and infliximab.
    Mössner R; Reich K
    Curr Probl Dermatol; 2009; 38():107-136. PubMed ID: 19710553
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Innovative uses of tumor necrosis factor alpha inhibitors.
    Mazza J; Rossi A; Weinberg JM
    Dermatol Clin; 2010 Jul; 28(3):559-75. PubMed ID: 20510765
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: clinical features and possible immunopathogenesis.
    Collamer AN; Battafarano DF
    Semin Arthritis Rheum; 2010 Dec; 40(3):233-40. PubMed ID: 20580412
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term management of erythrodermic psoriasis with anti-TNF agents.
    Romero-Maté A; García-Donoso C; Martinez-Morán C; Hernández-Núñez A; Borbujo J
    Dermatol Online J; 2010 Jun; 16(6):15. PubMed ID: 20579470
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Successful treatment of hidradenitis suppurativa with infliximab in a patient who failed to respond to etanercept.
    Poulin Y
    J Cutan Med Surg; 2009; 13(4):221-5. PubMed ID: 19706231
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-TNF agents and nail psoriasis: a single-center, retrospective, comparative study.
    Kyriakou A; Patsatsi A; Sotiriadis D
    J Dermatolog Treat; 2013 Jun; 24(3):162-8. PubMed ID: 22136334
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-TNF-α Drugs Differently Affect the TNFα-sTNFR System and Monocyte Subsets in Patients with Psoriasis.
    Gibellini L; De Biasi S; Bianchini E; Bartolomeo R; Fabiano A; Manfredini M; Ferrari F; Albertini G; Trenti T; Nasi M; Pinti M; Iannone A; Salvarani C; Cossarizza A; Pellacani G
    PLoS One; 2016; 11(12):e0167757. PubMed ID: 27936119
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and efficacy of the tumor necrosis factor antagonists.
    Bachmann F; Nast A; Sterry W; Philipp S
    Semin Cutan Med Surg; 2010 Mar; 29(1):35-47. PubMed ID: 20430306
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of TNF-α antagonists on the quality of life in selected skin diseases.
    Gisondi P; Girolomoni G
    G Ital Dermatol Venereol; 2013 Jun; 148(3):243-8. PubMed ID: 23670060
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TNFalpha and its receptors in psoriatic skin, before and after treatment with etanercept.
    Caldarola G; De Simone C; Carbone A; Tulli A; Amerio P; Feliciani C
    Int J Immunopathol Pharmacol; 2009; 22(4):961-6. PubMed ID: 20074459
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Survival rate of antitumour necrosis factor-α treatments for psoriasis in routine dermatological practice: a multicentre observational study.
    Esposito M; Gisondi P; Cassano N; Ferrucci G; Del Giglio M; Loconsole F; Giunta A; Vena GA; Chimenti S; Girolomoni G
    Br J Dermatol; 2013 Sep; 169(3):666-72. PubMed ID: 23647206
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of efalizumab in psoriasis patients previously treated with tumour necrosis factor blockers.
    Costanzo A; Talamonti M; Botti E; Spallone G; Papoutsaki M; Chimenti S
    Dermatology; 2009; 219(1):48-53. PubMed ID: 19372639
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Infections associated with the use of tumor necrosis factor-α inhibitors in psoriasis.
    Tan X; Balkrishnan R; Feldman SR
    J Drugs Dermatol; 2013 Mar; 12(3):e41-5. PubMed ID: 23545925
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of drug survival rates for adalimumab, etanercept and infliximab in patients with psoriasis vulgaris.
    Gniadecki R; Kragballe K; Dam TN; Skov L
    Br J Dermatol; 2011 May; 164(5):1091-6. PubMed ID: 21219290
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of infliximab on health-related quality of life and disease activity by body region in patients with moderate-to-severe psoriasis and inadequate response to etanercept: results from the PSUNRISE trial.
    Kalb RE; Blauvelt A; Sofen HL; Chevrier M; Amato D; Calabro S; Wang J; Schenkel B; Gottlieb AB
    J Drugs Dermatol; 2013 Aug; 12(8):874-80. PubMed ID: 23986160
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Efficacy of TNF-alpha antagonists for plaque-type psoriasis: a systematic review and graphical presentation].
    Levy-Roy A; Porcher R; de Fonclare AL; Morel P; Dupuy A
    Ann Dermatol Venereol; 2009 Apr; 136(4):315-22. PubMed ID: 19361697
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of Fcγ receptor polymorphisms in the response to anti–tumor necrosis factor therapy in psoriasis A pharmacogenetic study.
    Julià M; Guilabert A; Lozano F; Suarez-Casasús B; Moreno N; Carrascosa JM; Ferrándiz C; Pedrosa E; Alsina-Gibert M; Mascaró JM
    JAMA Dermatol; 2013 Sep; 149(9):1033-9. PubMed ID: 24048425
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adverse reactions during biological drug therapy in psoriasis:clinical series and a review of the literature.
    Montesu MA; Addis GM; Satta R; Cottoni F
    G Ital Dermatol Venereol; 2011 Aug; 146(4):273-81. PubMed ID: 21785393
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.